IRIS - Res&Arch Institutional Research Information System - Research & Archive

CRINO', Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.049
EU - Europa 2.228
AS - Asia 847
SA - Sud America 4
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.130
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.040
IE - Irlanda 598
IT - Italia 387
SE - Svezia 384
SG - Singapore 341
UA - Ucraina 271
VN - Vietnam 169
FI - Finlandia 166
HK - Hong Kong 163
RU - Federazione Russa 132
CN - Cina 115
DE - Germania 98
FR - Francia 60
GB - Regno Unito 45
KR - Corea 36
CH - Svizzera 22
RO - Romania 12
NL - Olanda 10
AT - Austria 8
BE - Belgio 8
CZ - Repubblica Ceca 8
PL - Polonia 8
CA - Canada 7
GR - Grecia 7
UZ - Uzbekistan 7
LB - Libano 6
IN - India 5
BR - Brasile 4
TR - Turchia 4
MX - Messico 2
A2 - ???statistics.table.value.countryCode.A2??? 1
DK - Danimarca 1
HU - Ungheria 1
MD - Moldavia 1
NG - Nigeria 1
PT - Portogallo 1
TW - Taiwan 1
Totale 6.130
Salva come PNG Salva come JPEG
Città #
Chandler 628
Dublin 598
San Mateo 345
Singapore 248
Boardman 225
Dong Ket 169
Hong Kong 163
Santa Clara 159
Andover 146
Medford 145
Princeton 143
Jacksonville 134
Altamura 129
Perugia 124
Lawrence 123
Ann Arbor 107
Wilmington 98
Beijing 61
Saint Petersburg 45
Seoul 36
Norwalk 31
San Paolo di Civitate 28
Helsinki 27
Des Moines 21
Munich 20
Redwood City 16
Ashburn 15
Falls Church 14
Moscow 14
Woodbridge 13
Bucharest 12
Lausanne 11
Dearborn 9
Los Angeles 9
Brussels 8
Den Haag 8
New York 8
Auburn Hills 7
Lappeenranta 6
Simi Valley 6
Shanghai 5
Arezzo 4
Chicago 4
Ottawa 4
Redmond 4
San Diego 4
Tappahannock 4
Chengdu 3
Costa Mesa 3
Dallas 3
Foligno 3
Frankfurt Am Main 3
Guangzhou 3
Houston 3
Izmir 3
Manassas 3
Marsciano 3
Nanjing 3
Nürnberg 3
Rome 3
Torgiano 3
Vienna 3
Asso 2
Brno 2
Cusano Milanino 2
Faenza 2
Hanover 2
Iglesias 2
Kansas City 2
Mcallen 2
Paris 2
Sesto Fiorentino 2
Shenyang 2
Terni 2
Toronto 2
Amelia 1
Azcapotzalco 1
Bologna 1
Brusciano 1
Cheltenham 1
Chieti 1
Chisinau 1
Città Di Castello 1
Clearwater 1
Dudley 1
Edinburgh 1
Florence 1
Forlì 1
Genova 1
Giarre 1
Giresun 1
Guttingen 1
Itabira 1
Kraków 1
Kunming 1
Lecco 1
Lisbon 1
Matupa 1
Monza 1
Mumbai 1
Totale 4.234
Salva come PNG Salva come JPEG
Nome #
Significato prognostico dell’espressione immunoistochimica di Insulin like growth facor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 101
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study 101
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer 93
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. 86
Afatinib In Egfr Mutant Non-small-cell Lung Cancer Patients With Acquired Resistance To Reversible Egfr-tkis 86
P-126 * PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER 82
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer 80
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 77
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 73
An approach for optimally extending mathematical models of signaling networks using omics data 71
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free servival in resected non-small-cell lung cancer patients. 70
Phase II study of weekly paclitaxel and trastuzumab in anthracycline and taxane pretreated patients with HER2 overexpressing metatastatic breast cancer 68
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer 67
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort 67
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. 66
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids 66
A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments 66
Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma 64
Acute myeloblastic leukemia after adjuvant chemo¬therapy with melphalan in breast cancer. Case report with cytogenetic analysis. 63
Non-coding RNAs in lung cancer 63
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 63
A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung 61
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. 60
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment 60
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 60
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 58
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 58
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 58
Carcinomi mammari "triple negative": studio dei fattori prognostici e predittivi. 57
Carcinomi mammari “triple negative”: studio dei fattori prognostici e predittivi 57
Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). 57
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 57
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study 57
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 55
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 55
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients 55
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. 54
Espressione dei recettori HER nei carcinomi non a piccole cellule del polmone 54
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease 54
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 54
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology 54
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 54
Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop 54
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 54
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment 53
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 53
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. 52
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390) 52
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors 51
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. 50
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 50
Microinvasive breast cancer: clinical pathological characteristics and treatment. Experience from two institutions 50
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 50
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients Results of the First Italian External Quality Assurance Scheme 50
Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. 49
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer 49
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 49
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 49
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 49
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology (vol 30, pg 142, 2012) 48
ERCC1 and RRM1 mRNA expression in resected patients with non-small-cell-lung-cancer (NSCLC). (A study of the Perugia multidisciplinary team for thoracic tumors) 47
MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non-small Cell Lung Cancer 47
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 47
Carcinomi mammari “tripli negativi”: significato biologico e prognostico dell’espressione di ERCC1. 46
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 46
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. 45
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 45
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology 45
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 45
Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT) 44
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients 44
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 44
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 44
Significato prognostico dell'espressione immunoistochimica di insulin like growth factor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 43
ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 43
A prospective study on survival in cancer patients with and without venous thromboembolism. 43
High coexpression of both insulin-like growth factor receptor 1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients 40
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 40
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 40
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 40
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? 40
Robustness of complex feedback systems: application to oncological biochemical networks 39
Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors 39
Risk Stratification Model For Resected Squamous Cell Lung Cancer (r-sqlc) Patients (pts) According To Clinical and Pathological Factors 39
Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer. 39
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer 38
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. 38
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 37
Increased levels of circulating DNA in patients with connective tissue diseases: a possible marker of disease activity in Sjögren’s syndrome 37
MYC and human telomerase (TERC) gene copy number gain in resected non-small cell lung cancer (NSCLC) 37
Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. 37
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 37
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) 36
Sunitinib Global Expanded-access Trial In Metastatic Renal Cell Carcinoma (mrcc) - Final Results 36
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study 36
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 36
Emerging drugs for small cell lung cancer - an update 35
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer A Phase-II Study 35
PD-L1 quantification across tumor types using the reverse phase protein microarray: Implications for precision medicine 34
PROGNOSTIC AND PREDICTIVE ROLE OF PIK3CA MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS TREATED WITH EGFR TYROSINE KINASE INHIBITORS (TKIS) 33
Totale 5.290
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.046
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020247 0 0 0 0 43 19 41 15 44 48 13 24
2020/2021975 4 36 50 39 319 79 48 5 99 41 64 191
2021/20221.152 29 237 12 75 19 11 7 446 14 12 119 171
2022/20232.061 149 394 16 180 157 206 0 96 772 1 69 21
2023/2024630 44 75 51 16 6 1 122 7 47 29 112 120
2024/2025588 43 168 100 47 230 0 0 0 0 0 0 0
Totale 6.411